Healthcare & Medical Devices Global On demand · 24-48h

Global HLA Typing Kit Market Strategic Research Report

Global HLA Typing Kit Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global HLA Typing Kit Market
$2892025
8.2%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Sequence-Specific Oligonucleotide (SSO) Typing Kits, Sequence-Specific Primer (SSP) Typing Kits, Sequence-Based Typing (SBT) Kits

By Application: Organ and Tissue Transplantation, Disease Diagnosis, Blood Transfusion, Forensic Analysis, Paternity Testing, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Thermo Fisher Scientific, CareDx(Olerup), ScienCell, Immucor, GenDx, LeanGene, Illumina, Fujirebio, SML Genetree, Bionobis, TBG Biotechnology Corp, BAG Diagnostics GmbH, Biofortuna, Roche Diagnostics, BD, Agilent

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 135 pages
Market size 2025
$289
Million USD
Forecast CAGR
8.2%
2025-2032
Forecast 2032
$501.8
Projected
リージョン
5
Asia Pacific · Latin America · MEA · Europe · North America

概観

Scope of the Report

The global HLA Typing Kit market size is predicted to grow from US$ 289 million in 2025 to US$ 499 million in 2032; it is expected to grow at a CAGR of 8.2% from 2026 to 2032.

The HLA typing kit market is expected to witness significant growth in the coming years due to the increasing demand for organ and stem cell transplantation, rising prevalence of autoimmune diseases, and advancements in HLA typing technologies. North America is expected to dominate the HLA typing kit market due to the presence of well-established healthcare infrastructure, increasing adoption of advanced technologies, and high healthcare expenditure.Europe is also a significant market for HLA typing kits due to the growing prevalence of autoimmune diseases and increasing government initiatives to promote organ transplantation.The Asia Pacific region is expected to witness rapid growth in the HLA typing kit market due to the rising healthcare expenditure, increasing awareness about organ transplantation, and growing demand for personalized medicine.The HLA typing kit market is highly competitive and fragmented, with several key players operating in the market. Some of the major players in the market include Thermo Fisher Scientific, Bio-Rad Laboratories, Illumina, and Immucor. These companies are focusing on product launches, collaborations, and acquisitions to strengthen their market position.Increasing demand for personalized medicine and targeted therapies is expected to create significant opportunities for the HLA typing kit market.Technological advancements in HLA typing technologies, such as next-generation sequencing and polymerase chain reaction (PCR), are expected to drive market growth.Growing awareness about the importance of HLA typing in organ and stem cell transplantation is expected to boost market demand.High cost associated with HLA typing kits and limited reimbursement policies in some regions may hinder market growth.Lack of skilled professionals and infrastructure in developing countries may limit the adoption of HLA typing kits.Ethical concerns related to organ transplantation and HLA typing may pose challenges to market growth.Overall, the HLA typing kit market is expected to witness significant growth in the coming years, driven by increasing demand for organ transplantation, advancements in HLA typing technologies, and growing prevalence of autoimmune diseases. However, challenges such as high cost and limited reimbursement policies may hinder market growth.

This report presents a comprehensive overview of the global HLA Typing Kit market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Sequence-Specific Oligonucleotide (SSO) Typing Kits
  • Sequence-Specific Primer (SSP) Typing Kits
  • Sequence-Based Typing (SBT) Kits

Segment by Application

  • Organ and Tissue Transplantation
  • Disease Diagnosis
  • Blood Transfusion
  • Forensic Analysis
  • Paternity Testing
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global HLA Typing Kit market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Organ and Tissue Transplantation, Disease Diagnosis, Blood Transfusion evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global HLA Typing Kit Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 8.2%
Regional growth momentum
Market share by segment
Key metrics
Base value
$289
2025
Forecast
$501.8
2032
CAGR
8.2%
2025–2032
リージョン
5
global
Key companies
Thermo Fisher ScientificCareDx(Olerup)ScienCellImmucorGenDxLeanGeneIlluminaFujirebio
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Sequence-Specific Oligonucleotide (SSO) Typing KitsSequence-Specific Primer (SSP) Typing KitsSequence-Based Typing (SBT) Kits
By Application
Organ and Tissue TransplantationDisease DiagnosisBlood TransfusionForensic AnalysisPaternity TestingOther

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Sequence-Specific Oligonucleotide (SSO) Typing Kits
  • 3.1.3 Sequence-Specific Primer (SSP) Typing Kits
  • 3.1.4 Sequence-Based Typing (SBT) Kits
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Organ and Tissue Transplantation
  • 4.1.3 Disease Diagnosis
  • 4.1.4 Blood Transfusion
  • 4.1.5 Forensic Analysis
  • 4.1.6 Paternity Testing
  • 4.1.7 Other
  • 4.1.8 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Thermo Fisher Scientific
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 CareDx(Olerup)
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 ScienCell
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Immucor
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 GenDx
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 LeanGene
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Illumina
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Fujirebio
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 SML Genetree
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Bionobis
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 TBG Biotechnology Corp
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 BAG Diagnostics GmbH
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Biofortuna
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Roche Diagnostics
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 BD
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Agilent
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global HLA Typing Kit market?
The global HLA Typing Kit market is estimated at US$ 289 million in 2025 (base year) and is projected to reach US$ 499 million by 2032.
What is the forecast CAGR for the HLA Typing Kit market?
The market is expected to grow at a CAGR of 8.2% from 2026 to 2032, expanding from US$ 289 million in 2025 to US$ 499 million in 2032, roughly 1.7 times its base-year value.
What is HLA Typing Kit?
The HLA typing kit market is expected to witness significant growth in the coming years due to the increasing demand for organ and stem cell transplantation, rising prevalence of autoimmune diseases, and advancements in HLA typing technologies. Some of the major players in the market include Thermo Fisher Scientific, Bio-Rad Laboratories, Illumina, and Immucor.
What are the main segments of the HLA Typing Kit market by type?
By type, the market is segmented into Sequence-Specific Oligonucleotide (SSO) Typing Kits, Sequence-Specific Primer (SSP) Typing Kits and Sequence-Based Typing (SBT) Kits.
Which applications drive demand in the HLA Typing Kit market?
Key applications covered include Organ and Tissue Transplantation, Disease Diagnosis, Blood Transfusion, Forensic Analysis, Paternity Testing and Other.
Who are the key players in the HLA Typing Kit market?
Key players profiled include Thermo Fisher Scientific, CareDx(Olerup), ScienCell, Immucor, GenDx, LeanGene, Illumina and Fujirebio, among 16 companies covered in total.
Which regions and countries are covered for HLA Typing Kit?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What challenges does the HLA Typing Kit market face?
However, challenges such as high cost and limited reimbursement policies may hinder market growth.
Who should buy the HLA Typing Kit market report?
The report is intended for manufacturers and solution providers, distributors and end users in Organ and Tissue Transplantation, Disease Diagnosis and Blood Transfusion, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the HLA Typing Kit market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.